

Augusto Villanueva

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8897328/augusto-villanueva-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139 papers	18,165 citations	60 h-index	134 g-index
155 ext. papers	23,522 ext. citations	9.7 avg, IF	7.69 L-index

#	Paper	IF	Citations
139	Digital-resolution and highly sensitive detection of multiple exosomal small RNAs by DNA toehold probe-based photonic resonator absorption microscopy.. <i>Talanta</i> , 2022 , 241, 123256	6.2	1
138	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.. <i>Gut</i> , 2022 ,	19.2	8
137	Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trial.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	2
136	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.. <i>Nature Cancer</i> , 2022 , 3, 386-401	15.4	8
135	DNA Methylation Profiling of Human Hepatocarcinogenesis. <i>Hepatology</i> , 2021 , 74, 183-199	11.2	10
134	Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA. <i>Hepatology Communications</i> , 2021 , 5, 1095-1105	6	2
133	Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma. <i>PLoS Genetics</i> , 2021 , 17, e1009589	6	1
132	Aramchol downregulates stearyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. <i>JHEP Reports</i> , 2021 , 3, 100237	10.3	10
131	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021 , 160, 2572-2584	13.3	28
130	Novel Non-Protein Biomarkers for Early Detection of Hepatocellular Carcinoma. <i>Engineering</i> , 2021 , 7, 1369-1369	9.7	1
129	Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. <i>Gut</i> , 2021 ,	19.2	8
128	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021 , 73 Suppl 1, 158-191	11.2	63
127	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021 , 73 Suppl 1, 115-127	11.2	35
126	Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. <i>Oncogene</i> , 2021 , 40, 140-151	9.2	28
125	Signaling pathways in hepatocellular carcinoma. <i>Advances in Cancer Research</i> , 2021 , 149, 63-101	5.9	8
124	The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. <i>Cancers</i> , 2021 , 13,	6.6	10
123	Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). <i>Gastroenterology</i> , 2021 , 161, 879-898	13.3	27

122	Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021 , 3, 100364	10.3	0
121	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 6	51.1	563
120	Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors. <i>Scientific Reports</i> , 2020 , 10, 5062	4.9	3
119	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020 , 73, 315-327	13.4	52
118	Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020 , 26, 823-831	4.5	11
117	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020 , 11, 291	17.4	102
116	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020 , 17, 139-152	24.2	215
115	Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing. <i>BMC Medicine</i> , 2020 , 18, 200	11.4	10
114	Liquid biopsy in the clinical management of hepatocellular carcinoma. <i>Gut</i> , 2020 , 69, 2025-2034	19.2	30
113	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019 , 79, 4326-4330	10.1	57
112	Mechanisms of Action of Drugs Effective in Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2019 , 14, 62-65	2.2	10
111	A phenotypical map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. <i>Histopathology</i> , 2019 , 74, 718-730	7.3	8
110	Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 1506-1519	6.1	9
109	The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. <i>JHEP Reports</i> , 2019 , 1, 120-130	10.3	19
108	ECatenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019 , 9, 1124-1141	24.4	214
107	Mitohormesis Primes Tumor Invasion and Metastasis. <i>Cell Reports</i> , 2019 , 27, 2292-2303.e6	10.6	44
106	Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. <i>Hepatology</i> , 2019 , 70, 2107-2122	11.2	9
105	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. <i>Breast Cancer Research</i> , 2019 , 21, 56	8.3	12

104	Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 380, 1450-1462	59.2	1441
103	The Impact of Translational Research in Hepatology. <i>Clinical Liver Disease</i> , 2019 , 13, 29-33	2.2	1
102	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. <i>Journal of Hepatology</i> , 2019 , 70, 1262-1277	13.4	90
101	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , 2019 , 68, 1065-1075	19.2	100
100	Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. <i>British Journal of Cancer</i> , 2019 , 121, 340-343	8.7	29
99	Liver Cancer 2019 , 89-100		1
98	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018 , 37, 3740-3752	9.2	61
97	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018 , 8, 11570	4.9	45
96	Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. <i>Oncoscience</i> , 2018 , 5, 209-211	0.8	9
95	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <i>Gut</i> , 2017 , 66, 530-540	19.2	113
94	Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. <i>Journal of Hepatology</i> , 2017 , 66, 952-961	13.4	84
93	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017 , 153, 812-826	13.3	371
92	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017 , 152, 745-761	13.3	535
91	Divergent evolutionary trajectories in transplanted tumor models. <i>Nature Genetics</i> , 2017 , 49, 1565-1566	36.3	10
90	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 67, 1222-1231	13.4	87
89	Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma. <i>Current Clinical Pathology</i> , 2017 , 125-135	0.1	2
88	Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 1-24	0.3	
87	Molecular profiling of liver cancer heterogeneity. <i>Discovery Medicine</i> , 2017 , 24, 117-125	2.5	3

86	Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016 , 13, 561-2	24.2	48
85	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <i>Journal of Hepatology</i> , 2016 , 65, 1031-1042	13.4	156
84	Liver capsule: Molecular-based signatures in hepatocellular carcinoma. <i>Hepatology</i> , 2016 , 63, 2018	11.2	4
83	A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. <i>Gut</i> , 2016 , 65, 1754-64	19.2	78
82	Clinical Trial Watch: Reports from the Liver Meeting , AASLD, San Francisco, November 2015. <i>Journal of Hepatology</i> , 2016 , 64, 1428-45	13.4	3
81	Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. <i>Clinical Liver Disease</i> , 2016 , 8, 100-104	2.2	12
80	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016 , 30, 879-890	24.3	119
79	The transition from inflammation to cancer in the liver. <i>Clinical Liver Disease</i> , 2016 , 8, 89-93	2.2	12
78	Selected summary for the 2015 Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE). <i>Hepatic Oncology</i> , 2016 , 3, 5-8	4	
77	Nontumor Prognostic Factors in Hepatocellular Carcinoma 2016 , 139-147		1
76	IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. <i>Gastroenterology</i> , 2016 , 151, 1192-1205	13.3	78
75	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015 , 149, 1226-1239	13.4	695
74	Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <i>Journal of Hepatology</i> , 2015 , 63, 753-62	13.4	3
73	DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. <i>Clinical Cancer Research</i> , 2015 , 21, 925-33	12.9	63
72	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015 , 47, 505-511	36.3	956
71	Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 1786-8	12.9	48
70	The future of patient-derived tumor xenografts in cancer treatment. <i>Pharmacogenomics</i> , 2015 , 16, 1671-88	11.2	36
69	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015 , 64, 1296-302	19.2	53

68 Signaling in hepatocellular carcinoma **2015**, 435-447

67 Advances in targeted therapies for hepatocellular carcinoma in the genomic era. *Nature Reviews Clinical Oncology*, **2015**, 12, 408-24 19.4 318

66 DNA methylation-based prognosis and epdrivers in hepatocellular carcinoma. *Hepatology*, **2015**, 61, 1945-56 11.2 237

65 Unique genomic profile of fibrolamellar hepatocellular carcinoma. *Gastroenterology*, **2015**, 148, 806-18.e15 13.3 81

64 Liquid biopsy in liver cancer. *Discovery Medicine*, **2015**, 19, 263-73 2.5 37

63 UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. *Cancer Cell*, **2014**, 25, 196-209 24.3 207

62 Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. *Nature Reviews Clinical Oncology*, **2014**, 11, 73-4 19.4 95

61 VEGF signaling in cancer treatment. *Current Pharmaceutical Design*, **2014**, 20, 2834-42 3.3 60

60 Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. *Gastroenterology*, **2013**, 144, 1024-30 13.3 151

59 Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. *Hepatology*, **2013**, 57, 120-30 11.2 45

58 Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. *Journal of Hepatology*, **2013**, 59, 392-5 13.4 17

57 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology*, **2013**, 144, 829-40 13.3 317

56 Medical therapies for hepatocellular carcinoma: a critical view of the evidence. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 34-42 24.2 243

55 A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. *Gastroenterology*, **2013**, 145, 176-187 13.3 254

54 Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. *World Journal of Gastroenterology*, **2013**, 19, 1193-9 5.6 28

53 Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. *Hepatology*, **2012**, 56, 2416-9 11.2 15

52 Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. *Clinical Cancer Research*, **2012**, 18, 4997-5007 12.9 195

51 Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. *Journal of Hepatology*, **2012**, 56, 1198-1200 13.4 2

50	Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. <i>Journal of Hepatology</i> , 2012 , 57, 213-4	13.4	5
49	Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <i>Journal of Hepatology</i> , 2012 , 56, 1343-50	13.4	156
48	Why men are at higher risk for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2012 , 57, 453-4	13.4	23
47	Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. <i>Clinical Cancer Research</i> , 2012 , 18, 1824-6	12.9	79
46	Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. <i>Hepatology</i> , 2012 , 56, 1361-70	11.2	30
45	Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. <i>Gastroenterology</i> , 2012 , 143, 1660-1669.e7	13.3	227
44	Emerging signaling pathways in hepatocellular carcinoma. <i>Liver Cancer</i> , 2012 , 1, 83-93	9.1	144
43	Gene signatures in the management of hepatocellular carcinoma. <i>Seminars in Oncology</i> , 2012 , 39, 473-85	5.5	53
42	Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. <i>Gastroenterology</i> , 2011 , 140, 1501-12.e2	13.3	307
41	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. <i>Gastroenterology</i> , 2011 , 140, 1618-28.e16	13.3	181
40	Hepatocellular carcinoma enters the sequencing era. <i>Gastroenterology</i> , 2011 , 141, 1943-5	13.3	5
39	Targeted therapies for hepatocellular carcinoma. <i>Gastroenterology</i> , 2011 , 140, 1410-26	13.3	360
38	Signaling pathways in hepatocellular carcinoma. <i>Oncology</i> , 2011 , 81 Suppl 1, 18-23	3.6	31
37	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2011 , 55, 1325-31	13.4	108
36	Depicting the role of TP53 in hepatocellular carcinoma progression. <i>Journal of Hepatology</i> , 2011 , 55, 724-725	13.4	39
35	Molecular pathogenesis of hepatocellular carcinoma. <i>Alcoholism: Clinical and Experimental Research</i> , 2011 , 35, 821-5	3.7	37
34	Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. <i>Hepatology</i> , 2011 , 54, 522-31	11.2	34
33	New strategies in hepatocellular carcinoma: genomic prognostic markers. <i>Clinical Cancer Research</i> , 2010 , 16, 4688-94	12.9	104

32	Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. <i>Seminars in Liver Disease</i> , 2010 , 30, 35-51	7.3	236
31	miRNA delivery: emerging therapy for hepatocellular carcinoma. <i>Gastroenterology</i> , 2010 , 138, 1202-4	13.3	13
30	Cancer gene discovery in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010 , 52, 921-9	13.4	152
29	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , 2010 , 52, 550-9	13.4	190
28	Genomic tracing of the elusive liver cancer ancestor. <i>Journal of Hepatology</i> , 2010 , 53, 578-9	13.4	1
27	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. <i>Annual Review of Medicine</i> , 2010 , 61, 317-28	17.4	189
26	Inherited hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2010 , 24, 725-34	2.5	17
25	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. <i>Cancer Research</i> , 2009 , 69, 7385-92	10.1	735
24	Lymphotoxins: new targets for hepatocellular carcinoma. <i>Cancer Cell</i> , 2009 , 16, 272-3	24.3	16
23	A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. <i>Nature Biotechnology</i> , 2009 , 27, 264-74	44.5	173
22	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , 2009 , 51, 725-33	13.4	182
21	Pathogenesis of hepatocellular carcinoma and molecular therapies. <i>Current Opinion in Gastroenterology</i> , 2009 , 25, 186-94	3	109
20	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. <i>Journal of Clinical Investigation</i> , 2009 , 119, 465-77	15.9	266
19	Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. <i>Gastroenterology</i> , 2008 , 134, 1521-31	13.3	79
18	Pivotal role of mTOR signaling in hepatocellular carcinoma. <i>Gastroenterology</i> , 2008 , 135, 1972-83, 1983.e1-11	13.3	563
17	Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. <i>Cancer Research</i> , 2008 , 68, 6779-88	10.1	463
16	Experimental models of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008 , 48, 858-79	13.4	174
15	Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. <i>Journal of Hepatology</i> , 2008 , 49, 1-5	13.4	29

14	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 3129-40	6.1	1072
13	Gene expression in fixed tissues and outcome in hepatocellular carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 1995-2004	59.2	979
12	Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. <i>Current Opinion in Oncology</i> , 2008 , 20, 444-53	4.2	51
11	Genomics and signaling pathways in hepatocellular carcinoma. <i>Seminars in Liver Disease</i> , 2007 , 27, 55-76	7.3	425
10	Current management of liver cancer. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 444-446	1.6	4
9	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. <i>Liver Transplantation</i> , 2006 , 12, 1747-54	4.5	15
8	A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. <i>Gastroenterology</i> , 2006 , 131, 1758-67	13.3	319
7	Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 79-83	2.2	16
6	Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 23, 1535-47	6.1	293
5	Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. <i>Transplantation Proceedings</i> , 2005 , 37, 3871-3	1.1	18
4	Update in the therapeutic management of irritable bowel syndrome. <i>Digestive Diseases</i> , 2001 , 19, 244-50	5.2	7
3	Unannotated small RNA clusters in circulating extracellular vesicles detect early stage liver cancer		2
2	MS.liverK: an R package for transcriptome-based computation of molecular subtypes and functional signatures in liver cancer		2
1	Signaling Pathways and Rationale for Molecular Therapies in Hepatocellular Carcinoma	368-381	